Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
27 February 1980Website:
http://www.bio-rad.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:25:06 GMTDividend
Analysts recommendations
Institutional Ownership
BIO Latest News
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?
SEATTLE, WA / ACCESSWIRE / June 3, 2024 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the Company is participating in the BIO International Convention occurring June 3-6, 2024 in San Diego, CA. The conference is known for being the largest biotechnology industry conference of the year and is expected to attract more than 18,000 attendees from around the world.
MINNEAPOLIS , May 31, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: William Blair 44th Annual Growth Conference June 4, 2024 9:20 AM CDT Jefferies Global Healthcare Conference June 6, 2024 9:30 AM EDT Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with more than 18,500 industry leaders from across the globe.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company will participate in the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024. During the conference, Enveric's management team plans to host meetings with pote.
MINNEAPOLIS, May 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) will showcase multiple applications of its recently launched MauriceFlex™ System at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics, taking place June 2 nd-6th in Anaheim, California. The MauriceFlex system is Bio-Techne's latest imaged capillary isoelectric focusing (icIEF) solution, which enables icIEF-based fractionation in addition to routine icIEF and capillary electrophoresis-sodium dodecyl sulfate (CE-SDS) assays.
Corporate presentation scheduled for Monday, June 3, 2024 at 2:30 P.M. PDT CARMIEL, Israel , May 29, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that Dror Bashan, its President and Chief Executive Officer, will present at the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California.
BERWYN, Pa.--(BUSINESS WIRE)-- #pharma--Virpax to Present at 2024 BIO International Convention.
Presentation to highlight Company's novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners through early oncologic drug discovery Presentation to highlight Company's novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners through early oncologic drug discovery
What type of business is Bio-Rad Laboratories?
Bio-Rad Laboratories, Inc. produces and supplies products for scientific research, healthcare, analytical chemistry, and other markets with products and systems used for separating complex chemical and biological materials and identifying, analyzing, and purifying their components. Bio-Rad operates in six industry segments: scientific research, clinical diagnostics, food industry, spectroscopy, and bioengineering. The segments operate worldwide. Bio-Rad's clients include hospitals, major research institutions, biotechnology and pharmaceutical companies, as well as secondary and tertiary academic institutions. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
What sector is Bio-Rad Laboratories in?
Bio-Rad Laboratories is in the Healthcare sector
What industry is Bio-Rad Laboratories in?
Bio-Rad Laboratories is in the Medical Devices industry
What country is Bio-Rad Laboratories from?
Bio-Rad Laboratories is headquartered in United States
When did Bio-Rad Laboratories go public?
Bio-Rad Laboratories initial public offering (IPO) was on 27 February 1980
What is Bio-Rad Laboratories website?
https://www.bio-rad.com
Is Bio-Rad Laboratories in the S&P 500?
Yes, Bio-Rad Laboratories is included in the S&P 500 index
Is Bio-Rad Laboratories in the NASDAQ 100?
No, Bio-Rad Laboratories is not included in the NASDAQ 100 index
Is Bio-Rad Laboratories in the Dow Jones?
No, Bio-Rad Laboratories is not included in the Dow Jones index
When does Bio-Rad Laboratories report earnings?
The next expected earnings date for Bio-Rad Laboratories is 02 August 2024